• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

认知障碍与帕金森病:文献综述

Cognitive disorders and parkinson's disease: a literature review.

作者信息

Jamora Roland Dominic G, Untalan Liamuel Giancarlo V, Santiago Donna Mae Lyn B, Tan Louis C S

机构信息

Division of Adult Neurology, Department of Neurosciences, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.

Section of Neurology, Department of Internal Medicine, Cardinal Santos Medical Center, San Juan City, Philippines.

出版信息

J Neural Transm (Vienna). 2025 Jul 18. doi: 10.1007/s00702-025-02983-3.

DOI:10.1007/s00702-025-02983-3
PMID:40679622
Abstract

Parkinson's Disease (PD) is a movement disorder characterized by tremors, rigidity, and bradykinesia, accompanied by several non-motor symptoms, with cognitive impairment as one of the most debilitating. This narrative review of literature aims to provide a general overview on the defining features, pathologic changes, and management principles of cognitive changes in PD. A literature review was conducted by searching the terms "Cognition" OR "Cognitive Decline", AND "Parkinson's Disease" in PubMed, Scopus, and Google Scholar. Mild cognitive impairment (PD-MCI) and dementia (PDD) have been well-defined with consensus criteria. Recent researches have focused on pathophysiologic changes, identifying patterns of atrophy, as well as corresponding neurochemical insults. These have been primarily targeted in the existing pharmacologic literature, with evidence for non-pharmacologic therapies still lacking. Cognitive changes in PD range from a spectrum of mild cognitive impairment (PD-MCI) to dementia (PDD). Evidence exists for clinical and pathologic mechanisms which guide current and future therapeutic principles. Current trends of research are focused on the potential of discovering preventive therapies strengthens the need for more high-level evidence in the future.

摘要

帕金森病(PD)是一种运动障碍性疾病,其特征为震颤、僵硬和运动迟缓,并伴有多种非运动症状,其中认知障碍是最使人衰弱的症状之一。这篇文献综述旨在对帕金森病认知改变的定义特征、病理变化及管理原则进行概述。通过在PubMed、Scopus和谷歌学术中搜索“认知”或“认知衰退”以及“帕金森病”等关键词进行文献综述。轻度认知障碍(PD-MCI)和痴呆(PDD)已通过共识标准得到明确界定。最近的研究集中在病理生理变化、识别萎缩模式以及相应的神经化学损伤方面。这些主要是现有药理学文献的研究目标,非药物治疗的证据仍然缺乏。帕金森病的认知改变范围从轻度认知障碍(PD-MCI)到痴呆(PDD)。存在指导当前和未来治疗原则的临床和病理机制的证据。当前的研究趋势集中在发现预防性治疗方法的潜力上,这加强了未来对更多高级别证据的需求。

相似文献

1
Cognitive disorders and parkinson's disease: a literature review.认知障碍与帕金森病:文献综述
J Neural Transm (Vienna). 2025 Jul 18. doi: 10.1007/s00702-025-02983-3.
2
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.用于路易体痴呆、帕金森病痴呆及帕金森病认知障碍的胆碱酯酶抑制剂
Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD006504. doi: 10.1002/14651858.CD006504.pub2.
3
One-year practice effects predict long-term cognitive outcomes in Parkinson's disease.一年的练习效果可预测帕金森病的长期认知结果。
J Parkinsons Dis. 2025 Apr 29:1877718X251339585. doi: 10.1177/1877718X251339585.
4
Mild cognitive impairment is not predictive of dementia up to 15 years after subthalamic deep brain stimulation in Parkinson's disease.在帕金森病中,丘脑底核深部脑刺激术后长达15年的时间里,轻度认知障碍并不能预测痴呆。
J Parkinsons Dis. 2025 Jun;15(4):879-891. doi: 10.1177/1877718X251334049. Epub 2025 May 20.
5
Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment.尼麦角林治疗痴呆及其他与年龄相关的认知障碍形式的疗效。
Cochrane Database Syst Rev. 2001;2001(4):CD003159. doi: 10.1002/14651858.CD003159.
6
Understanding the Patient Experience of Advanced Parkinson's Disease: Qualitative Research with Patients and Expert Clinicians to Identify Symptoms and Associated Health-Related Quality of Life Impacts.了解晚期帕金森病患者的体验:对患者和临床专家进行定性研究以确定症状及相关的健康相关生活质量影响。
Neurol Ther. 2025 May 13. doi: 10.1007/s40120-025-00747-5.
7
The Global Landscape of Genetic Variation in Parkinson's disease: Multi-Ancestry Insights into Established Disease Genes and their Translational Relevance.帕金森病遗传变异的全球格局:对既定疾病基因及其转化相关性的多血统见解
medRxiv. 2025 Jul 11:2025.07.08.25330815. doi: 10.1101/2025.07.08.25330815.
8
Efficacy of Combined Herbal and Western Medicine Based on Traditional Chinese Medicine for Mild Cognitive Impairment and Dementia in Parkinson's Disease: A Systematic Review and Meta-Analysis.基于中医的中西医结合疗法治疗帕金森病轻度认知障碍和痴呆的疗效:一项系统评价与荟萃分析
Complement Med Res. 2025;32(3):244-259. doi: 10.1159/000545937. Epub 2025 May 15.
9
The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.左旋多巴/卡比多巴肠凝胶对晚期帕金森病患者“关”期的长期影响:一项系统评价
Adv Ther. 2021 Jun;38(6):2854-2890. doi: 10.1007/s12325-021-01747-1. Epub 2021 May 20.
10
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).脑脊液tau蛋白及脑脊液tau蛋白与β淀粉样蛋白比值在轻度认知障碍(MCI)患者中用于诊断阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.

本文引用的文献

1
Galantamine-Memantine Combination in the Treatment of Parkinson's Disease Dementia.加兰他敏与美金刚联合治疗帕金森病痴呆
Brain Sci. 2024 Nov 21;14(12):1163. doi: 10.3390/brainsci14121163.
2
Risk of Dementia in Parkinson's Disease: A Systematic Review and Meta-Analysis.帕金森病患者痴呆风险:系统评价和荟萃分析。
Mov Disord. 2024 Oct;39(10):1697-1709. doi: 10.1002/mds.29918. Epub 2024 Jul 22.
3
Alpha-Synuclein Pre-Formed Fibrils Injected into Prefrontal Cortex Primarily Spread to Cortical and Subcortical Structures.注射到前额叶皮质的α-突触核蛋白预形成纤维主要扩散到皮质和皮质下结构。
J Parkinsons Dis. 2024;14(1):81-94. doi: 10.3233/JPD-230129.
4
Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction.帕金森病和其他突触核蛋白病中的阿尔法-突触核蛋白:从明显的神经退行性变回到早期突触功能障碍。
Cell Death Dis. 2023 Mar 1;14(3):176. doi: 10.1038/s41419-023-05672-9.
5
Predicting cognitive decline in Parkinson's disease using FDG-PET-based supervised learning.基于 FDG-PET 的有监督学习预测帕金森病认知下降。
J Clin Invest. 2022 Oct 17;132(20). doi: 10.1172/JCI157074.
6
Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: A systematic review and meta-analysis.路易体谱系疾病中血脑屏障破坏和神经退行性变的生物流体标志物:系统评价和荟萃分析。
Parkinsonism Relat Disord. 2022 Aug;101:119-128. doi: 10.1016/j.parkreldis.2022.06.004. Epub 2022 Jun 20.
7
Current concepts in treating mild cognitive impairment in Parkinson's disease.帕金森病轻度认知障碍的治疗新理念。
Neuropharmacology. 2022 Feb 1;203:108880. doi: 10.1016/j.neuropharm.2021.108880. Epub 2021 Nov 10.
8
Treatment of Parkinson's Disease with Cognitive Impairment: Current Approaches and Future Directions.帕金森病伴认知障碍的治疗:当前方法与未来方向
Behav Sci (Basel). 2021 Apr 17;11(4):54. doi: 10.3390/bs11040054.
9
Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease.帕金森病各认知领域的胆碱能神经支配模式。
Mov Disord. 2021 Mar;36(3):642-650. doi: 10.1002/mds.28360. Epub 2020 Nov 2.
10
Cognitive impairment in Parkinson's disease: A clinical and pathophysiological overview.帕金森病中的认知障碍:临床与病理生理学概述
J Neurol Sci. 2020 Dec 15;419:117177. doi: 10.1016/j.jns.2020.117177. Epub 2020 Oct 11.